# HRR Prevalence in LatAm PROSPECT Study

> **NCT04962880** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 388 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04962880
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2022-04-08
- **Final completion:** 2022-04-08
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962880, "HRR Prevalence in LatAm PROSPECT Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04962880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*